Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth welcomes bapineuzumab findings

Wyeth welcomes bapineuzumab findings

17th June 2008

Wyeth pharmaceuticals has welcomed the findings of phase II clinical trials of the bapineuzumab drug, which it has been developing in collaboration with Ireland-based Elan Corporation.

Bapineuzumab has been designed as a treatment for Alzheimer’s disease and the results of the latest tests have provided enough encouragement for the two companies to give the go-ahead for phase III trials.

Elan’s chief executive Kelly Martin suggested that the progress of the drug reflected the company’s commitment to bringing new products to market and the potential utility of taking an “amyloid approach” to treating Alzheimer’s disease.

“We are encouraged by these findings,” said Bernard Poussot, president and chief executive of Wyeth.

“We remain driven by science and focused on patients as we work to bring this treatment to those who desperately need new options,” he added.

Products developed by Wyeth include those used to treat animal health problems and the company insists that it is among the world’s leading pharmaceutical research and development operators.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.